Edivoxetine

From WikiMD.org
Jump to navigation Jump to search

Edivoxetine (pronounced: ed-ih-vox-e-teen) is a norepinephrine reuptake inhibitor (NRI) that was under development by Eli Lilly for the adjunctive treatment of major depressive disorder (MDD) and attention-deficit hyperactivity disorder (ADHD). The development was discontinued in 2013.

Etymology

The term "Edivoxetine" is derived from the Latin roots "Edivo" meaning "to draw out" and "xetine" which is a common suffix used in the names of Selective serotonin reuptake inhibitors (SSRIs).

Pharmacology

Edivoxetine works by inhibiting the reuptake of norepinephrine, a neurotransmitter, thereby increasing the levels of norepinephrine in the brain. This mechanism of action is similar to that of other norepinephrine reuptake inhibitors.

Clinical Trials

Edivoxetine was tested in several clinical trials for its efficacy in treating major depressive disorder and attention-deficit hyperactivity disorder. However, the development of the drug was discontinued in 2013 due to unsatisfactory results.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski